CRISPR Therapeutics has presented initial clinical trial results for CTX310, a gene-editing treatment aimed at lowering triglycerides and LDL cholesterol, showing durable genetic modifications at the European Society of Cardiology congress.

New analyses from the REDUCE-IT® trial and EPA mechanistic data are scheduled for presentation at the European Society of Cardiology (ESC) Congress in 2026.